Drug intelligence / Profile preview

B7H3 CAR iNK cells

Development stage: Preclinical
Lead developer: Fate Therapeutics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

B7H3 CAR iNK cells (specifically developed as FT573 by Fate Therapeutics) are an off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cell therapy designed to target B7-H3 (CD276), a pan-cancer antigen overexpressed in many solid tumors and hematologic malignancies. The therapeutic candidate is engineered with four key functional components: a chimeric antigen receptor (CAR) optimized for NK cell biology that targets B7-H3; a high-affinity, non-cleavable CD16 (hnCD16) Fc receptor to enhance antibody-dependent cellular cytotoxicity (ADCC) when combined with monoclonal antibodies; a membrane-bound IL-15/IL-15 receptor fusion (IL-15RF) to promote cytokine-autonomous persistence and activation; and a CD38 knockout (CD38-KO) to prevent fratricide and improve metabolic fitness in the tumor microenvironment.

Other names: B7-H3 CAR iNK cellsB-7-H3 CAR iNK cellsB 7-H3 CAR iNK cellsB7-H3 CAR-iNK cellsB-7-H3 CAR-iNK cellsB 7-H3 CAR-iNK cellsB7H3 CAR-iNK cellsB-7H3 CAR-iNK cellsB 7H3 CAR-iNK cellsanti-B7-H3 CAR-iNK cellsanti-B-7-H3 CAR-iNK cellsanti-B 7-H3 CAR-iNK cellsanti-B7H3 CAR iNK cellsanti-B-7H3 CAR iNK cellsanti-B 7H3 CAR iNK cells

Targets

MICB (Major histocompatibility complex class i-related protein B)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)CD38 (Cluster of Differentiation 38)B7-H3

Beyond the preview

Go deeper on B7H3 CAR iNK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B7H3 CAR iNK cells.

Explore the full profile